Answers are grounded in this paper and cite their sources.
SUMMARY Excessive bleeding accounts for a significant incidence of morbidity and mortality resulting from a variety of conditions including congenital and acquired bleeding disorders, trauma, and surgery. A complex network of cellular and plasma components are involved in the process of controlling excessive bleeding, a process known as hemostasis. When excessive bleeding does occur, there are a wide variety of agents with diverse mechanisms of action that can promote hemostasis. These agents include blood products, biologicals such as recombinant proteins, synthetic medications, and topical agents. Historically, non‐specific agents such as fresh frozen plasma, cryoprecipitate and antifibrinolytic agents have been the standard therapies for the management of excessive bleeding. These, however, all have significant limitations. Recently, recombinant factor VIIa (rFVIIa) was licensed for use in patients with hemophilia and inhibitors to factors VIII or IX. Since its licensure, it has been used in a wide variety of conditions with excessive bleeding leading to often dramatic results. Another novel agent is factor XIII (FXIII) which is currently in clinical trials. Although data regarding its use in conditions other than FXIII deficiency is lacking, it is expected that FXIII will become another effective agent in the management of excessive bleeding.
No takes yet. Share an insight, caveat, or question.
Guy Young (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: